Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Total Non-Current Liabilities (2017 - 2025)

Corcept Therapeutics' Total Non-Current Liabilities history spans 9 years, with the latest figure at $173.7 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 18.24% year-over-year to $173.7 million; the TTM value through Dec 2025 reached $173.7 million, up 18.24%, while the annual FY2025 figure was $173.7 million, 18.24% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $173.7 million at Corcept Therapeutics, down from $177.6 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $177.6 million in Q3 2025 and bottomed at $40.6 million in Q1 2021.
  • The 5-year median for Total Non-Current Liabilities is $95.1 million (2023), against an average of $97.1 million.
  • The largest annual shift saw Total Non-Current Liabilities decreased 0.95% in 2021 before it surged 129.65% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $47.5 million in 2021, then surged by 52.48% to $72.5 million in 2022, then skyrocketed by 44.16% to $104.5 million in 2023, then surged by 40.55% to $146.9 million in 2024, then increased by 18.24% to $173.7 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Total Non-Current Liabilities are $173.7 million (Q4 2025), $177.6 million (Q3 2025), and $150.3 million (Q2 2025).